MedTrace Logo

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-09

Study results available
· View outcomes & findings →

Summary

This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.

Conditions

  • Non Small Cell Lung Cancer
  • Stage I Lung Cancer
  • Stage Ib Lung Carcinoma
  • Stage IA Lung Carcinoma AJCC V7
  • Stage IIA Lung Carcinoma
  • Stage IIIA Lung Carcinoma

Interventions

DRUG

Vitamin A Compound

Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection

PROCEDURE

Therapeutic Conventional Surgery

Participants randomized to this arm will receive surgical resection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • William J Petty, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-19
Primary Completion
2022-12-09
Completion
2022-12-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03870529 on ClinicalTrials.gov